Max Healthcare Institute Ltd Q4 FY25 Earnings Analysis

Published 8 Aug 2026 | Healthcare Services | Market Cap: ₹1.1L Cr

Price

1,070

Market Cap

₹1.1L Cr

P/E Ratio

70.9

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Max Healthcare Institute Ltd Q4 FY25 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Max Healthcare Institute Ltd share price analysis?

Max Healthcare Institute Ltd currently shows a neutral. The stock trades at a P/E of 70.9 with a market cap of ₹105,110. Investors should review the full earnings analysis for detailed insights.

Is Max Healthcare Institute Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Healthcare Services this season

  • Thyrocare Technologies Ltd (Q4 FY25)

    Thyrocare Technologies Ltd Q4 FY25 quarterly results analysis. - Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% yea

  • Narayana Hrudayalaya Ltd (Q4 FY25)

    Narayana Hrudayalaya Ltd Q4 FY25 quarterly results analysis. - Organic growth trajectory is established with reasonable, steady growth expected over time. Marke

  • Syngene International Ltd (Q4 FY25)

    Syngene International Ltd Q4 FY25 quarterly results analysis. - Q3 FY'25 showed an 11% revenue growth after two quarters of decline, indicating a return to grow

  • Dr Agarwals Health Care Ltd (Q4 FY25)

    Dr Agarwals Health Care Ltd Q4 FY25 quarterly results analysis. - Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from